Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Aptevo Therapeutics Inc News

    3,00 € +0,33% +0,01 €
    10.04.24 09:31:48 L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A403XC
    ISIN: US03835L3069
    US-Symbol: APVO
    Typ: Aktie

    Aptevo Therapeutics Inc News

    28.12.23 - PR Newswire
    Thinking about buying stock in Fusion Pharmaceuticals, Aptevo Therapeutics, Blink Charging, Ampio Pharmaceuticals, or Bitcoin Depot?
    Thinking about buying stock in Fusion Pharmaceuticals, Aptevo Therapeutics, Blink Charging, Ampio Pharmaceuticals, or Bitcoin Depot? PR Newswire
    10.08.23 - PR Newswire
    Thinking about buying stock in Mogo Inc, Rigetti Computing, Aptevo Therapeutics, Milestone Pharmaceuticals, or Wheels Up Experience?
    Thinking about buying stock in Mogo Inc, Rigetti Computing, Aptevo Therapeutics, Milestone Pharmaceuticals, or Wheels Up Experience? PR Newswire
    12.12.22 - PR Newswire
    Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals?
    Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? PR Newswire
    19.09.22 - ACCESSWIRE
    Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
    Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types
    11.08.22 - ACCESSWIRE
    Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
    SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on ...
    09.06.22 - ACCESSWIRE
    Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
    Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-​evaluable Patients Treated to Date
    12.05.22 - ACCESSWIRE
    Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
    SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on developing ...
    12.04.22 - ACCESSWIRE
    APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
    Preclinical Data Support Potential for APVO442 in Difficult-​to-Treat Types of Prostate Cancer, Including Metastatic Castration-​Resistant Disease
    29.03.22 - ACCESSWIRE
    Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
    Patients in Both Monotherapy and Combination Arms in Multi-​Cohort Trial Have Achieved Transplant Eligible Status
    24.03.22 - ACCESSWIRE
    Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
    SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-​stage biotechnology company focused on developing novel immuno-​oncology ...
    09.02.22 - ACCESSWIRE
    Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
    APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site
    21.01.22 - ACCESSWIRE
    Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
    Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022
    15.12.21 - ACCESSWIRE
    Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
    LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today ...
    23.11.21 - ACCESSWIRE
    Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
    SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on ...
    15.11.21 - ACCESSWIRE
    Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
    SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on ...
    12.11.21 - ACCESSWIRE
    Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
    SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on ...
    11.11.21 - ACCESSWIRE
    Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
    Data support Advancement into the Clinic
    11.11.21 - ACCESSWIRE
    Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
    Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific
    27.10.21 - ACCESSWIRE
    Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
    SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on ...
    26.10.21 - ACCESSWIRE
    Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
    SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-​stage biotechnology company focused on ...

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »